Prestige Consumer Healthcare Q1 FY2027 earnings: Acquisition activity lifts revenue but pressures GAAP profit

Prestige Consumer Healthcare (NYSE: PBH) reported fiscal Q1 2027 revenue of $265.7 million, up 6.5% year over year, while GAAP diluted EPS fell to $0.61 from $0.95; adjusted diluted EPS increased to $0.98 from $0.95. Organic revenue grew 3.2%, but acquisition-related expenses and Pillar5 remediation costs reduced reported profitability, creating a significant gap between GAAP and adjusted results.

Core financial results

Reported growth for the quarter ended June 30, 2026 included a $5.9 million contribution from Breathe Right, which closed late in the quarter. Excluding acquisition revenue and foreign-exchange effects, organic revenue was $259.8 million, compared with $251.6 million a year earlier.

GAAP gross and operating margins declined as the company recorded acquired-inventory adjustments, Pillar5 remediation expenses and transaction-related costs. Adjusted net income was slightly lower, but adjusted EPS rose because diluted weighted-average shares declined by about 4.5%.

Business and segment performance

North American OTC Healthcare revenue increased 6.4% to $226.2 million. The Gastrointestinal, Dermatological, and Cough, Cold & Allergy categories contributed organic growth, while Breathe Right added revenue to the newly established Wellness, Sleep & Other category. North American contribution margin nevertheless declined to $87.0 million from $91.4 million.

International OTC Healthcare revenue rose 6.9% to $39.5 million, including $1.4 million from Breathe Right. International contribution margin increased to $14.5 million from $13.9 million.

The company established the Wellness, Sleep & Other category and renamed certain existing categories following the Breathe Right transaction. These presentation changes do not affect consolidated revenue.

Acquisition activity widened the gap between reported and adjusted profitability

Prestige recorded $22.8 million of adjustments to calculate adjusted EBITDA. These included $2.8 million of acquired-inventory fair-value amortization, $7.1 million of Pillar5 remediation and related overhead costs, and $12.8 million of acquisition costs within general and administrative expenses.

As a result, GAAP gross margin was 51.3%, compared with an adjusted gross margin of 55.0%. Even after the exclusions, adjusted gross margin remained below the prior-year level of 56.2%, while adjusted EBITDA margin slipped to 31.6% from 31.9%.

The timing of the transactions is important. Breathe Right closed in mid-June and contributed only $5.9 million during the quarter, while LaCorium closed in July after quarter-end. Prestige therefore recorded substantial acquisition and integration expenses before receiving a full quarter of revenue from the acquired businesses.

Profitability, cash flow and balance sheet

Cash from operating activities declined to $70.8 million from $79.0 million. Free cash flow before the company’s acquisition-cost adjustment was $67.1 million, down from $78.2 million, partly reflecting capital expenditures of $3.7 million versus $0.8 million. Adjusted free cash flow reached $83.7 million after adding back $16.7 million of paid acquisition and other costs. The company also attributed the adjusted cash-flow performance to working-capital timing.

Prestige paid $1.045 billion for acquisitions during the quarter and received an equal amount in term-loan proceeds. Total debt principal was $2.045 billion at June 30, while cash was $89.1 million, leaving net debt of approximately $2 billion. Interest expense increased to $13.9 million from $10.2 million.

After quarter-end, Prestige issued $400 million of 6.25% senior notes due in 2034 to replace the same principal amount of notes previously due in fiscal 2028. The refinancing extended the maturity rather than reducing debt and moved the company’s nearest debt maturity to 2031.

Fiscal 2027 guidance

Prestige raised its fiscal 2027 revenue, adjusted EPS and adjusted free cash flow outlook entirely to incorporate Breathe Right and LaCorium. Organic growth guidance remained unchanged, indicating that the higher consolidated outlook reflects the acquisitions rather than an increase in the company’s underlying growth assumptions.

The guidance reconciliation lists projected GAAP diluted EPS of $4.18 to $4.28. However, Prestige said that this calculation includes only first-quarter adjustments and does not quantify additional acquisition and Pillar5-related adjustments for the remainder of fiscal 2027, which it said are likely to be significant.

Management’s view

Management described consumer consumption across its leading brands as healthy despite a challenging consumer environment. Portfolio diversification and marketing activity are expected to help the company manage continuing supply variability for Clear Eyes.

For the acquired businesses, management plans to expand Breathe Right internationally while supporting domestic category growth. It also expects Dermal Therapy, acquired through LaCorium, to benefit from therapeutic skin-care category growth, product innovation and geographic expansion. Management expects both acquisitions to become increasingly accretive as integration progresses and synergies emerge.

Risks investors should monitor

• Integration and remediation costs: Pillar5 remediation and acquisition-related expenses materially reduced GAAP margins. Additional adjustments for the rest of fiscal 2027 have not been quantified.
• Higher leverage: Net debt was approximately $2 billion, and interest expense increased year over year. The company’s ability to generate cash and deleverage is therefore an important follow-up measure.
• Acquisition-dependent guidance: The raised full-year outlook comes entirely from Breathe Right and LaCorium, while organic growth guidance remains at 1% to 3%. Integration delays or weaker acquired-brand performance could affect the outlook.
• Cash-flow comparability: Adjusted free cash flow benefited from working-capital timing and the add-back of acquisition costs. GAAP operating cash flow and free cash flow before that adjustment both declined.
• Clear Eyes supply variability: Management continues to face volatile supply for Clear Eyes while operating against a challenging consumer backdrop.

Summary

Prestige Consumer Healthcare delivered 3.2% organic growth and received an initial revenue contribution from Breathe Right, but acquisition and Pillar5-related costs caused GAAP earnings and margins to decline. Adjusted earnings remained comparatively stable, and the full-year outlook increased to include Breathe Right and LaCorium. The main issues to watch are whether the acquired brands deliver the expected revenue and synergies, whether reported margins recover as one-time costs recede, and how quickly cash generation reduces the company’s higher debt load.